Search
Paclitaxel Treatment Options in Kentucky
A collection of 297 research studies where Paclitaxel is the interventional treatment. These studies are located in the Kentucky, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
289 - 297 of 297
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
Completed
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2010
Locations: Central Baptist Hospital, Lexington, Kentucky
Conditions: Coronary Stenosis
A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Completed
The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2010
Locations: Pfizer Investigational Site, Louisville, Kentucky +3 locations
Conditions: Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC). The safety of this combination will also be evaluated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2010
Locations: ImClone Investigational Site, Louisville, Kentucky
Conditions: Non-small Cell Lung Cancer
CPG 7909 Injection in Non-Small Cell Lung Cancer
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: Kentucky Cancer Clinic, Hazard, Kentucky
Conditions: Carcinoma, Non-Small Cell Lung
Phase II CT-2103/Carboplatin in Ovarian Cancer
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: University of Louisville, Louisville, Kentucky
Conditions: Ovarian Neoplasm
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
Conditions: Kidney Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky
Conditions: Colorectal Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky
Conditions: Prostate Cancer
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
Completed
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2006
Locations: Pfizer Investigational Site, Louisville, Kentucky +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
289 - 297 of 297